Faron Pharmaceuticals Oy - ESG Rating & Company Profile powered by AI
If you work at Faron Pharmaceuticals Oy and you wish to use your ESG aseessment, please contact us. This dashboard includes a questions and answers section about Faron Pharmaceuticals Oy. Comprehensive Sustainability analysis of Faron Pharmaceuticals Oy can be reached by signing up for free.
Faron Pharmaceuticals Oy in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.0; made up of an environmental score of 5.3, social score of 4.8 and governance score of 8.0.
6.0
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
483 | Wakamoto Pharmaceutical Co Ltd | 6.1 | High |
483 | aTyr Pharma Inc | 6.1 | High |
498 | Faron Pharmaceuticals Oy | 6.0 | High |
498 | Cann Group Ltd | 6.0 | High |
498 | Biosynex SA | 6.0 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Faron Pharmaceuticals Oy have an accelerator or VC vehicle to help deliver innovation?
Does Faron Pharmaceuticals Oy disclose current and historical energy intensity?
Does Faron Pharmaceuticals Oy report the average age of the workforce?
Does Faron Pharmaceuticals Oy reference operational or capital allocation in relation to climate change?
Does Faron Pharmaceuticals Oy disclose its ethnicity pay gap?
Does Faron Pharmaceuticals Oy disclose cybersecurity risks?
Does Faron Pharmaceuticals Oy offer flexible work?
Does Faron Pharmaceuticals Oy have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Faron Pharmaceuticals Oy disclose the number of employees in R&D functions?
Does Faron Pharmaceuticals Oy conduct supply chain audits?
Does Faron Pharmaceuticals Oy disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Faron Pharmaceuticals Oy conduct 360 degree staff reviews?
Does Faron Pharmaceuticals Oy disclose the individual responsible for D&I?
Does Faron Pharmaceuticals Oy disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Faron Pharmaceuticals Oy disclose current and / or historical scope 2 emissions?
Does Faron Pharmaceuticals Oy disclose water use targets?
Does Faron Pharmaceuticals Oy have careers partnerships with academic institutions?
Did Faron Pharmaceuticals Oy have a product recall in the last two years?
Does Faron Pharmaceuticals Oy disclose incidents of discrimination?
Does Faron Pharmaceuticals Oy allow for Work Councils/Collective Agreements to be formed?
Has Faron Pharmaceuticals Oy issued a profit warning in the past 24 months?
Does Faron Pharmaceuticals Oy disclose parental leave metrics?
Does Faron Pharmaceuticals Oy disclose climate scenario or pathway analysis?
Does Faron Pharmaceuticals Oy disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Faron Pharmaceuticals Oy disclose the pay ratio of women to men?
Does Faron Pharmaceuticals Oy support suppliers with sustainability related research and development?
Does Faron Pharmaceuticals Oy disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Faron Pharmaceuticals Oy reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Faron Pharmaceuticals Oy involved in embryonic stem cell research?
Does Faron Pharmaceuticals Oy disclose GHG and Air Emissions intensity?
Does Faron Pharmaceuticals Oy disclose its waste policy?
Does Faron Pharmaceuticals Oy report according to TCFD requirements?
Does Faron Pharmaceuticals Oy disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Faron Pharmaceuticals Oy disclose energy use targets?
Does Faron Pharmaceuticals Oy disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Faron Pharmaceuticals Oy have a policy relating to cyber security?
Have a different question?
Potential Risks for Faron Pharmaceuticals Oy
These potential risks are based on the size, segment and geographies of the company.
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. The company also develops Haematokine, a new chemical entity AOC3 inhibitor for the treatment of hematological malignancies and bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.